Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6766 to 6780 of 8908 results

  1. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    In development Reference number: GID-TA11092 Expected publication date: TBC

  2. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued Reference number: GID-NG10397

  3. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

  4. The Assurance Nasal Alar SpO2 Sensor (discontinued)

    Discontinued Reference number: GID-MT510

  5. Abicipar pegol for treating wet age-related macular degeneration [ID1533]

    In development Reference number: GID-TA10511 Expected publication date: TBC

  6. Surgical site infections: prevention and treatment - Update

    Discontinued Reference number: GID-NG10374

  7. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099

    In development Reference number: GID-TA11640 Expected publication date: TBC

  8. Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088

    Discontinued Reference number: GID-TA11702

  9. Lung transplantation with ex-vivo perfusion

    Discontinued Reference number: GID-IP1046

  10. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued Reference number: GID-IP2806

  11. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development Reference number: GID-IPG10394 Expected publication date: TBC

  12. Ex utero intrapartum therapy for fetal obstruction

    Discontinued Reference number: GID-IP1156

  13. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development Reference number: GID-TA11582 Expected publication date: TBC

  14. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]

    In development Reference number: GID-TA11588 Expected publication date: TBC

  15. ALXN1840 for treating Wilson disease [ID6422]

    In development Reference number: GID-TA11449 Expected publication date: TBC